Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Gains from Investment Securities (2016 - 2025)

Coherus Oncology's Gains from Investment Securities history spans 13 years, with the latest figure at -$281000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 89.11% year-over-year to -$281000.0; the TTM value through Dec 2025 reached -$2.8 million, down 281.89%, while the annual FY2025 figure was $18000.0, 115.79% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$281000.0 at Coherus Oncology, down from $19000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.8 million in Q1 2023 and bottomed at -$2.6 million in Q4 2024.
  • The 5-year median for Gains from Investment Securities is $120256.5 (2022), against an average of $124107.3.
  • The largest YoY upside for Gains from Investment Securities was 1482.5% in 2024 against a maximum downside of 1158.54% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$705000.0 in 2021, then tumbled by 245.25% to -$2.4 million in 2022, then surged by 91.58% to -$205000.0 in 2023, then plummeted by 1158.54% to -$2.6 million in 2024, then surged by 89.11% to -$281000.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Gains from Investment Securities are -$281000.0 (Q4 2025), $19000.0 (Q3 2025), and $16000.0 (Q2 2025).